Shannon Byler

Shannon Byler

Auto-generated profile, based on publicly available information

Shannon Byler

Cancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2014 in Cancers
Verified
Journal Article
Open access
PDF file
GHGenevieve Housman
Genevieve Housman
SBShannon Byler
Shannon Byler
SHSarah Heerboth
Sarah Heerboth
KLKarolina Lapinska
Karolina Lapinska
MLMckenna Longacre
Mckenna Longacre
Sibaji SarkarSibaji Sarkar
Sibaji Sarkar
Cancers have the ability to develop resistance to traditional therapies, and the increasing prevalence of these drug resistant cancers necessitates further research and treatment development. This paper outlines the current knowledge of mechanisms that promote or enable drug resistance, such as drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, and the epithelial-mesenchymal transition, as well as how inherent tumor cell heterogeneity plays a role in drug resistance. It also describes the epigenetic modifications that can induce drug resistance and considers how such epigenetic factors may contribute to the development of cancer progenitor cells, which are not killed by conventional cancer therapies. Lastly, this review concludes with a discussion on the best treatment options for existing drug resistant cancers, ways to prevent the formation of drug resistant cancers and cancer progenitor cells, and future directions of study.

26 February 2015 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
SHSarah Heerboth
Sarah Heerboth
GHGenevieve Housman
Genevieve Housman
MLMeghan Leary
Meghan Leary
MLMckenna Longacre
Mckenna Longacre
SBShannon Byler
Shannon Byler
Sibaji SarkarSibaji Sarkar
Sibaji Sarkar
EMT and MET comprise the processes by which cells transit between epithelial and mesenchymal states, and they play integral roles in both normal development and cancer metastasis. This article reviews these processes and the molecular pathways that contribute to them. First, we compare embryogenesis and development with cancer metastasis. We then discuss the signaling pathways and the differential expression and down‐regulation of receptors in both tumor cells and stromal cells, which play a role in EMT and metastasis. We further delve into the clinical implications of EMT and MET in several types of tumors, and lastly, we discuss the role of epigenetic events that regulate EMT/MET processes. We hypothesize that reversible epigenetic events regulate both EMT and MET, and thus, also regulate the development of different types of metastatic cancers.

Verified
Journal Article
Open access
PDF file
Sibaji SarkarSibaji Sarkar
Sibaji Sarkar
GHGarrick Horn
Garrick Horn
KMKimberly Moulton
Kimberly Moulton
AOAnuja Oza
Anuja Oza
SBShannon Byler
Shannon Byler
MLMcKenna Longacre
McKenna Longacre
Carcinogenesis involves uncontrolled cell growth, which follows the activation of oncogenes and/or the deactivation of tumor suppression genes. Metastasis requires down-regulation of cell adhesion receptors necessary for tissue-specific, cell–cell attachment, as well as up-regulation of receptors that enhance cell motility. Epigenetic changes, including histone modifications, DNA methylation, and DNA hydroxymethylation, can modify these characteristics. Targets for these epigenetic changes include signaling pathways that regulate apoptosis and autophagy, as well as microRNA. We propose that predisposed normal cells convert to cancer progenitor cells that, after growing, undergo an epithelial-mesenchymal transition. This process, which is partially under epigenetic control, can create a metastatic form of both progenitor and full-fledged cancer cells, after which metastasis to a distant location may occur. Identification of epigenetic regulatory mechanisms has provided potential therapeutic avenues. In particular, epigenetic drugs appear to potentiate the action of traditional therapeutics, often by demethylating and re-expressing tumor suppressor genes to inhibit tumorigenesis. Epigenetic drugs may inhibit both the formation and growth of cancer progenitor cells, thus reducing the recurrence of cancer. Adopting epigenetic alteration as a new hallmark of cancer is a logical and necessary step that will further encourage the development of novel epigenetic biomarkers and therapeutics.

1 March 2014
Verified
Journal Article
Closed access
SBShannon Byler
Shannon Byler
SGSarah Goldgar
Sarah Goldgar
SHSarah Heerboth
Sarah Heerboth
MLMeghan Leary
Meghan Leary
GHGenevieve Housman
Genevieve Housman
Sibaji SarkarSibaji Sarkar
Sibaji Sarkar